The Role of the High-Sensitivity C-Reactive Protein in Patients with Stable Non-Cystic Fibrosis Bronchiectasis

Table 2

Characteristics and outcomes of the 69 stable bronchiectasis patients.

	hs-CPR < 4.26	hs-CRP ≥ 4.26	𝑃 value
	𝑛=38	𝑛=31
Age (years)	56.2±13.7	59.0±13.9	0.406
Gender (M/F)	21/17	18/13	0.815
BMI (kg/m^2)	22.0±3.4	22.0±3.4	0.990
Smoking
Never	30	25	0.862
Ex/current	8	6
PFT
FVC (L)	2.25±0.81	1.85±0.71	0.034
FVC (%)	72.5±16.4	61.1±21.0	0.014
FEV1 (L)	1.69±0.74	1.34±0.59	0.038
FEV1 (%)	67.6±21.4	56.6±23.5	0.046
FEV1/FVC (%)	73.5±11.0	71.3±10.4	0.401
Total IgE (KU/L)	137.8±320.3	170.9±490.6	0.737
ECP (mcg/L)	17.5±17.8	24.5±36.7	0.304
6 MWT
Rest O2 sat (%)	96.4±1.6	93.5±4.4	0.001
Lowest O2 sat (%)	87.7±6.4	85.2±10.2	0.237
ΔO2 sat (%)	8.7±6.1	8.4±7.4	0.816
Walk distance (meters)	469.3±78.2	436.1±104.1	0.136
HRCT scores	21.7±9.8	28.1±13.1	0.004
Bacterial colony
Ps. aeruginosa	6	11	0.115
Others	8	4
Normal flora/no growth	24	16
Hospitalizations before recruitment (times/year)
<2	35	21	0.01
≥2	3	10

Abbreviations: hs-CRP: high-sensitivity C-reactive protein, PFT: pulmonary function test, IgE: immunoglobulin E, ECP: eosinophilic cationic protein, 6 MWT: 6-minute walk test, ΔO₂ sat (%): oxygenation difference between rest and lowest during 6-minute walk test, and HRCT: high-resolution computed tomography.